Mission
Early Stage Partners is proud to serve our limited partners and to support leading technology companies in the Midwest.
We believe that by providing much-needed capital, advice and connections to promising early stage companies, we can breed success for entrepreneurs, investors and the region as a whole.
About ESP
Early Stage Partners is a venture capital firm founded in 2001 with the belief that the Midwest could produce a significant number of attractive technology companies.
Since then, this belief has been borne out. The Midwest is experiencing a surge of entrepreneurial energy and, as a result, is generating high quality investment opportunities. Early Stage Partners has been pleased to capitalize on this trend.
ESP Fund I, launched in 2002, and ESP Fund II, launched in 2008, are both expected to achieve top quartile returns among funds of a similar size and vintage. Early Stage Partners experienced a banner year in 2014, when portfolio companies TOA Technologies, Simbionix and Reverse Medical were sold to strategic investors for a combined value approaching $750 million. TOA Technologies, sold to Oracle, remains the largest ever exit for an Ohio-based software company.
Press Release
HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors
Acquisition will Accelerate Global Expansion of Company’s Breakthrough Edison® Histotripsy Platform and [...]
Read MorePress Release
HistoSonics Raises $102 Million for Liver Cancer Treatment
A noninvasive technology that uses sound waves to destroy tumors gets a [...]
Read MorePress Release
FDA AWARDS HISTOSONICS CLEARANCE OF ITS FIRST-OF-A-KIND EDISON® HISTOTRIPSY SYSTEM
HistoSonics®, (www.histosonics.com), the manufacturer of the Edison® System and novel histotripsy therapy [...]
Read MorePress Release
HistoSonics Announces First Ever KidneyTumor Treatment Using Histotripsy
Leeds Teaching Hospitals NHS Trust, (UK) Performs Non-Invasive Histotripsy in Patient with [...]
Read More